Deferred Tax Assets, Operating Loss Carryforwards of NeuroSense Therapeutics Ltd. from 31 Dec 2021 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: NeuroSense Therapeutics Ltd. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2021 to 31 Dec 2024.
NeuroSense Therapeutics Ltd. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $5,688,000, a 72% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

NeuroSense Therapeutics Ltd. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$5,688,000	+$2,373,000	+72%	31 Dec 2024	20-F	07 Apr 2025	2024	FY
Q4 2023	$3,315,000	+$1,666,000	+101%	31 Dec 2023	20-F	07 Apr 2025	2024	FY
Q4 2022	$1,649,000	+$932,000	+130%	31 Dec 2022	6-K	17 Jun 2024	2023	FY
Q4 2021	$717,000			31 Dec 2021	6-K	17 Jun 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.